

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): December 21, 2018

**MEDOVEX CORP.**

(Exact Name of Registrant as Specified in Charter)

Nevada (State or other jurisdiction of incorporation)	001-36763 (Commission File Number)	46-3312262 (IRS Employer Identification No.)
2380 Old Milton Parkway Alpharetta, Georgia (Address of principal executive offices)		30009 (Zip Code)

Registrant's telephone number, including area code: (844) 633-6839

Copies to:

Arthur S. Marcus, Esq  
Sichenzia Ross Ference LLP  
1185 Avenue of the Americas  
37<sup>th</sup> Floor  
New York, New York 10036  
(212) 930-9700  
(212) 930-9725 (fax)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On December 21, 2018, Medovex Corp. (the “Company”) entered into a Second Amended Warrant Agreement (the “Amended Warrant Agreement”) with Issuer Direct Corporation, fka Interwest Transfer Co., (the “Warrant Agent”). The Company and the Warrant Agent entered into the original Warrant Agreement on December 24, 2014 in connection with the Company’s initial public offering of its units (the “Original Warrant Agreement”) and entered into the first Amended Warrant Agency Agreement on February 4, 2016. The Warrant Agreement, as amended, set forth the terms of the warrants (the “Warrants”) included in the Company’s units and appointed the Warrant Agent to act as warrant agent for the Warrants.

The Company and the Warrant Agent entered into the Second Amended Warrant Agreement in order to amend 3.2 of the Warrant Agreement, as amended, to change the Expiration Date from December 24, 2018 to December 24, 2019.

The foregoing description of the Second Amended Warrant Agreement is qualified in its entirety by reference to the Second Amended Warrant Agreement, a copy of which is attached hereto as Exhibit 4.1 and is hereby incorporated by reference into this Item 1.01.

**Item 3.03 Material Modification to Right of Security Holders**

As set forth in Item 1.01 above, the Company amended the forms of their publicly traded Warrants to increase the duration of the Warrants for one year until December 24, 2019.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
4.1	<a href="#"><u>Second Amended Warrant Agreement by and between the Company and Issuer Direct Corporation dated December 21, 2018</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDOVEX CORP.**

Date: December 21, 2018

By: /s/ William Horne

William Horne  
Chief Executive Officer

---



## SECOND AMENDED WARRANT AGENCY AGREEMENT

This Agreement is made and entered into as of this 21<sup>st</sup> day of December, 2018 by and between Medovex Corporation, a Nevada corporation with its principal offices at 2380 Old Milton Parkway, Alpharetta, Georgia 30009 (the “MDVX” or the “Company”) and Issuer Direct Corporation, with offices at 1981 Murray Holiday Road, Suite 102, Salt Lake City, Utah 84117 (“Warrant Agent”). The Warrant Agent and the Company are collectively referred to as the “Parties”.

WHEREAS, the Company and the Warrant Agent entered into a Warrant Agency Agreement dated December 24, 2014 (the “Original Warrant Agreement”);

WHEREAS, the Company and the Warrant Agent entered into an Amended Warrant Agency Agreement dated February 4, 2016 (the “First Amended Warrant Agency Agreement”);

WHEREAS, the Company has determined that it is in the best interests of the Company to extend the Exercise Period of the Warrant from December 24, 2018 to December 24, 2019.

WHEREAS, Section 9.8 of the Original Warrant Agreement, as amended, provides that amendments may be made to the terms of the Original Warrant Agreement without consent of the holders provided that such changes do not adversely affect the interests of the registered holders and that the changes may accordingly be made by the Company and the Warrant Agent.

WHEREAS, the changes set forth herein do not adversely affect the interests of the Registered holders of the Warrants.

All capitalized terms used herein and not defined herein shall have the same meaning as these in the Original Warrant Agreement, as amended. Unless otherwise specifically modified herein, the provisions of the Original Warrant Agreement, as amended, shall remain in full force and effect.

NOW, THEREFORE, in consideration of the mutual terms and covenants contained herein, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

1. Modification of Exercise Period. (a) The Parties hereby agree that Section 3.2 of the Original Warrant Agreement, as amended, is hereby modified to change the Expiration Date from December 24, 2018 to December 24, 2019 (the “New Expiration Date”).

2. Parties in Interest. This Agreement is made solely for the benefit of the Warrant Holders and the Company, and their respective controlling persons, directors and officers, and their respective successors, assigns, executors and administrators. No other person shall acquire or have any right under or by virtue of this Agreement.

3. Headings. The section headings in this Agreement have been inserted as a matter of convenience of reference and are not a part of this Agreement.

4. Counterparts. This Agreement may be executed in any number of counterparts, each of which together shall constitute one and the same instrument.

[Signature Page Follows]

---

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, as of the day and year first above written.

MEDOVEX CORPORATION

ISSUER DIRECT CORPORATION

By: /s/ William Horne

By: /s/ Kurt D. Hughes

Name: William Horne

Name: Kurt D. Hughes

Title: Chief Executive Officer

Title: President

---

